Aptar Reports Third Quarter 2021 Results

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today reported third quarter results for 2021.

Third Quarter 2021 Summary
*Reported sales grew 9%, primarily driven by double-digit core sales growth in Beauty + Home and Food + Beverage from a combination of price increases and volume growth
*Core sales (excluding currency effects) increased 8%
*Pharma sales declined slightly compared to the prior year
*Reported earnings per share totaled $0.70 and included restructuring charges ($0.12), an unrealized loss on an equity investment ($0.10) resulting from the mark-to-market position of our investment in PureCycle Technologies, Inc. (purification recycling technology) and acquisition costs ($0.02)
*Reported net income totaled $47 million
*Acquisition Updates:
-Completed the acquisition of 80% of Weihai Hengyu Medical Products, adding elastomeric and plastic component manufacturing capabilities in China for injectable drug delivery
-Completed the acquisition of a majority stake in Voluntis, a provider of digital therapeutic solutions
details at: https://www.aptar.com/wp-content/uploads/2021/10/PR-Aptar-Q3-Oct-28-2021.pdf

Back To Top
×Close search